Azitra, Inc., a clinical-stage biopharmaceutical company, announced it has regained compliance with all NYSE American continued listing standards after resolving previous deficiencies. This means the 'below compliance' indicator will be removed, and Azitra will no longer be listed as noncompliant on the NYSE American website. The company remains under monitoring but is focused on advancing its dermatology and cosmetic protein programs, including ATR-COSF and ATR-04. This compliance restoration supports Azitra's ongoing efforts to build shareholder value through its innovative therapies and clinical trials.
KE Holdings Inc. reported Q2 2026 earnings with an EPS of $0.42, surpassing the $0.31 consensus estimate. Although revenue declined 5.7% year-over-year to about $3.60 billion, the company doubled its net income thanks to effective cost controls and o...
Stellar's developer activity surged 125% year-over-year by Q2 2026, reaching a record 2,968 monthly active developers, placing it second globally behind Ethereum and ahead of Solana and Bitcoin. This growth is fueled by builders focusing on practical...
Michael Burry has issued a warning that the rapid growth in AI data centers is fueled by complex financial arrangements like circular financing and off-balance-sheet vehicles, which obscure true leverage and risk, similar to the 2008 financial crisis...
Tesla has removed all public references to its solar roof product from its website, effectively ending the initiative. The solar roof, introduced nearly a decade ago as a luxury integrated solar solution, struggled with high costs, production issues,...
US spot Bitcoin ETFs saw a massive inflow of $685 million on August 20, 2026, with BlackRock's iShares Bitcoin Trust (IBIT) capturing $503 million of that total. This surge is part of a broader trend, with August inflows surpassing $2 billion and cum...
